QEEG/Genomic Analysis For Predicting Therapeutic Outcome

Abstract

Using a combinatorial algorithm comprised of quantitative EEG features and at least one pharmacogenomic variable, a significantly higher predictive accuracy and usability is achieved as compared to other current methods of clinical decision support for guided pharmacotherapy. The method produces a report with actionable findings for the treating physician, recommending for and/or against multiple drug classes and agents from among the available treatments for mental health disorders. While predictive accuracy for pharmacogenomic testing averages 73%, the presently disclosed combinatorial algorithms achieve a significantly higher rate of accuracy at 91%.

We claim: 
     
         1 . A method, comprising:
 a) collecting an electroencephalogram and a plurality of cells from a patient exhibiting at least one symptom of a diagnosed psychiatric disorder;   b) converting said electroencephalogram into at least one quantitative electroencephalographic (QEEG) feature variable;   c) identifying at least one genotype in said plurality of cells;   d) comparing said at least one QEEG feature variable to a first database to create a first therapy list prioritized according to a first predicted efficacy score, said first therapy list comprising a first recommended therapy;   e) comparing said at least one genotype to a second database to create a second therapy list prioritized according to a second predicted efficacy score, said second therapy list comprising a second recommended therapy;   f) matching said first therapy list and said second therapy list to create a final therapy list prioritized according to a combined first and second efficacy score, said final therapy list comprising a final recommended therapy; and   g) administering said final recommended therapy to said patient under conditions such that said at least one symptom is reduced, wherein said selected therapy comprises a combined first and second efficacy score that is within a preferred range.   
     
     
         2 . The method of  claim 1 , wherein said final recommended therapy is different from said first recommended therapy and said second recommended therapy. 
     
     
         3 . The method of  claim 1 , wherein said first recommended therapy and said second recommended therapy are the same. 
     
     
         4 . The method of  claim 1 , wherein said first recommended therapy and said second recommended therapy are different. 
     
     
         5 . A method, comprising:
 a) collecting an electroencephalogram and a plurality of cells from a patient exhibiting at least one symptom of a diagnosed psychiatric disorder;   b) converting said electroencephalogram into at least one quantitative electroencephalographic (QEEG) feature variable;   c) comparing said at least one QEEG feature variable to a first database to identify a prioritized list of recommended drugs;   d) processing said prioritized list of recommended drugs with an in vitro enzyme metabolism assay using said plurality of cells to identify a list of said recommended drugs prioritized by metabolic rate;   e) selecting a preferred recommended drug by identification of a non-metabolic drug biomarker in said plurality of cells that matches at least one drug on said metabolic rate prioritized list of recommended drugs;   f) administering said preferred recommended drug to said patient under conditions such that said at least one symptom is reduced.   
     
     
         6 . The method of  claim 5 , wherein said non-metabolic drug biomarker is a blood based biomarker. 
     
     
         7 . The method of  claim 5 , wherein said non-metabolic drug biomarker is a cell based biomarker. 
     
     
         8 . A method, comprising:
 a) collecting an electroencephalogram and a plurality of cells from a patient exhibiting at least one symptom of a diagnosed psychiatric disorder;   b) converting said electroencephalogram into at least one quantitative electroencephalographic (QEEG) feature variable, said QEEG feature variable having a predetermined drug efficacy predictive value;   c) identifying at least one genotype in said plurality of cells, said at least one genotype having a predetermined drug efficacy predictive value;   d) combining said QEEG feature variable predetermined drug efficacy predictive value and said at least one genotype predetermined drug efficacy predictive value to create a list of recommended drugs prioritized by an efficacy score; and   e) administering at least one of said recommended drugs to said patient under conditions such that said at least one symptom is reduced, wherein said efficacy score of said selected drug is within a preferred range.   
     
     
         9 . The method of  claim 8 , wherein said at least one genotype encodes a non-metabolic drug efficacy predictor. 
     
     
         10 . The method of  claim 8 , wherein said at least one genotype encodes a metabolic drug efficacy predictor. 
     
     
         11 . The method of  claim 10 , wherein said method further comprises measuring a metabolic rate of said at least one said recommended drugs using said metabolic drug efficacy predictor. 
     
     
         12 . A method, comprising:
 a) collecting an electroencephalogram and a plurality of cells from a patient exhibiting at least one symptom of a diagnosed psychiatric disorder;   b) converting said electroencephalogram into at least one quantitative electroencephalographic (QEEG) feature variable;   c) comparing said at least one QEEG feature variable to a first database to identify a prioritized list of recommended drugs;   d) processing said prioritized list of recommended drugs with at least one metabolic genotype using said plurality of cells to identify a list of said recommended drugs prioritized by metabolic rate;   e) selecting a preferred recommended drug by identification of a non-metabolic drug biomarker in said plurality of cells that matches at least one drug on said metabolic rate genotype prioritized list of recommended drugs;   f) administering said preferred recommended drug to said patient under conditions such that said at least one symptom is reduced.   
     
     
         13 . The method of  claim 12 , wherein said plurality of cells is derived from a patient biopsy.